Article

Deal announced: Chinese firm to license artificial tear products

Shanghai, China-Aqueous Pharma Ltd. and Shanghai Zinox Chemical Technologies Ltd. will join efforts to produce three patented artificial tear products developed by Frank J. Holly, MD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
Related Content
CORXEL submits NDA for LNZ100 in China for presbyopia treatment
July 28th 2025

CORXEL submits NDA for LNZ100 in China for presbyopia treatment

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA
July 26th 2025

Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis suggests potential benefits
July 25th 2025

NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis suggests potential benefits

(Image credit: AdobeStock/Bonsales) Q&A: Natalie Afshari, MD, FACS, on-label pediatric IOLs: turning advocacy into access
July 24th 2025

Q&A: Natalie Afshari, MD, FACS, championing on-label pediatric IOLs: turning advocacy into access

© 2025 MJH Life Sciences

All rights reserved.